The last NephJC of the year brought us a cool discussion on if cooling dialysate could help mitigate the effects of intradialytic hypotension. Get caught up with the chat in the latest edition of #TenTweetNephJC.
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
The last NephJC of the year brought us a cool discussion on if cooling dialysate could help mitigate the effects of intradialytic hypotension. Get caught up with the chat in the latest edition of #TenTweetNephJC.
Last #TenTweetNephJC thread of 2022
— Nephrology Journal Club (@NephJC) December 28, 2022
Intradialytic hypotension (IDH) is deeply unpleasant but very common. We hope cooling dialysate to cause vasoconstriction prevents IDH, helping prevent myocardial stunning.
So does cooling dialysate improve cardiovascular outcomes? pic.twitter.com/mmNoIxlDxk